Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - CytomX Therapeutics, Inc. | ctmx-ex321_13.htm |
| EX-31.2 - EX-31.2 - CytomX Therapeutics, Inc. | ctmx-ex312_7.htm |
| EX-31.1 - EX-31.1 - CytomX Therapeutics, Inc. | ctmx-ex311_9.htm |
| EX-23.2 - EX-23.2 - CytomX Therapeutics, Inc. | ctmx-ex232_387.htm |
| 10-K - 10-K - CytomX Therapeutics, Inc. | ctmx-10k_20171231.htm |
CONSENT OF ERNST & YOUNG LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 333-214418 and 333-216567) and Form S-8 (Nos. 333-207694, 333-209992 and 333-215795) of CytomX Therapeutics, Inc. of our report dated March 7, 2018, with respect to the financial statements of CytomX Therapeutics, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2017.
/s/ Ernst & Young LLP
Redwood City, California
March 7, 2018